LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.21 -3.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.19

Max

1.25

Belangrijke statistieken
By Trading Economics
Inkomsten	-103K -6.6M
Werknemers	42

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+200% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	19M 92M
Vorige openingsprijs	4.41
Vorige sluitingsprijs	1.21

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mei 2026, 23:41 UTC

Winsten

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mei 2026, 21:40 UTC

Winsten

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mei 2026, 23:34 UTC

Marktinformatie

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mei 2026, 23:12 UTC

Winsten

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mei 2026, 23:11 UTC

Winsten

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:07 UTC

Winsten

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mei 2026, 23:05 UTC

Winsten

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mei 2026, 23:04 UTC

Winsten

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mei 2026, 22:25 UTC

Marktinformatie

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mei 2026, 22:05 UTC

Marktinformatie

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mei 2026, 21:58 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:47 UTC

Marktinformatie

Winsten

Costco Posts 13% Sales Growth in April -- Market Talk

6 mei 2026, 21:46 UTC

Winsten

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mei 2026, 21:40 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:35 UTC

Marktinformatie

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mei 2026, 21:32 UTC

Populaire aandelen

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mei 2026, 21:29 UTC

Winsten

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

200% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.75 USD 200%

Hoogste 4 USD

Laagste 3.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.